AstraZeneca inks exclusive global license agreement with Dizal Pharmaceutical for novel oral EGFR inhibitor Zegfrovy for lung cancer

AstraZeneca, a global, science-led biopharmaceutical company, has entered into an exclusive license agreement with Dizal Pharmaceutical Co., Ltd for Zegfrovy (sunvozertinib), a novel oral irreversible epidermal growth factor

To access the full article, please log in or subscribe.